Randomised clinical trial: transoral incisionless fundoplication vs. sham intervention to control chronic GERD.

Autor: Håkansson B; Department of Surgery, Ersta Hospital, Karolinska Institutet, Danderyds Hospital, Stockholm, Sweden., Montgomery M; Department of Surgery, Ersta Hospital, Karolinska Institutet, Danderyds Hospital, Stockholm, Sweden., Cadiere GB; Department of Surgery and Gastroenterology, Park Leopold Clinic, CHIREC, Brussels, Belgium., Rajan A; Department of Surgery and Gastroenterology, Park Leopold Clinic, CHIREC, Brussels, Belgium., Bruley des Varannes S; CHU Hotel Dieu Institut des Maladies de l' Appareil Digestif, Nantes, France., Lerhun M; CHU Hotel Dieu Institut des Maladies de l' Appareil Digestif, Nantes, France., Coron E; CHU Hotel Dieu Institut des Maladies de l' Appareil Digestif, Nantes, France., Tack J; Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium., Bischops R; Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium., Thorell A; Department of Surgery, Ersta Hospital, Karolinska Institutet, Danderyds Hospital, Stockholm, Sweden., Arnelo U; Department of Surgery, Centre for Digestive Diseases, Karolinska University Huddinge Hospital, Karolinska Institutet, Stockholm, Sweden., Lundell L; Department of Surgery, Centre for Digestive Diseases, Karolinska University Huddinge Hospital, Karolinska Institutet, Stockholm, Sweden.
Jazyk: angličtina
Zdroj: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2015 Dec; Vol. 42 (11-12), pp. 1261-70. Date of Electronic Publication: 2015 Oct 13.
DOI: 10.1111/apt.13427
Abstrakt: Background: Until recently only two therapeutic options have been available to control symptoms and the esophagitis in chronic gastro-oesophageal reflux disease (GERD), i.e. lifelong proton pump inhibitor (PPI) therapy or anti-reflux surgery. Lately, transoral incisionless fundoplication (TIF) has been developed and found to offer a therapeutic alternative for these patients.
Aim: To perform a double-blind sham-controlled study in GERD patients who were chronic PPI users.
Methods: We studied patients with objectively confirmed GERD and persistent moderate to severe GERD symptoms without PPI therapy. Of 121 patients screened, we finally randomised 44 patients with 22 patients in each group. Those allocated to TIF had the TIF2 procedure completed during general anaesthesia by the EsophyX device with SerosaFuse fasteners. The sham procedure consisted of upper GI endoscopy under general anaesthesia. Neither the patient nor the assessor was aware of the patients' group affiliation. The primary effectiveness endpoint was the proportion of patients in clinical remission after 6-month follow-up. Secondary outcomes were: PPI consumption, oesophageal acid exposure, reduction in Quality of Life in Reflux and Dyspepsia and Gastrointestinal Symptom Rating Scale scores and healing of reflux esophagitis.
Results: The time (average days) in remission offered by the TIF2 procedure (197) was significantly longer compared to those submitted to the sham intervention (107), P < 0.001. After 6 months 13/22 (59%) of the chronic GERD patients remained in clinical remission after the active intervention. Likewise, the secondary outcome measures were all in favour of the TIF2 procedure. No safety issues were raised.
Conclusion: Transoral incisionless fundoplication (TIF2) is effective in chronic PPI-dependent GERD patients when followed up for 6 months. Clinicaltrials.gov: CT01110811.
(© 2015 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje